Cyclopharm PP&E per Employee
The PP&E per Employee of Cyclopharm (CYC.AX) as of Nov 3, 2026 is 372,133.89 AUD. In the previous year, PP&E per Employee was 363,884.17 AUD — a change of 2.27% (higher).
Get this data via API
Financial Data API
PP&E per Employee
372,133.89AUD
YoY
2.27%
Last updated:
The Cyclopharm PP&E per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | PP&E per Employee | YoY |
|---|---|---|
| 372,133.89AUD | +2.27% | |
| 363,884.17AUD | +42.60% | |
| 255,172.22AUD | +39.19% | |
| 183,322.22AUD | +5.66% | |
| 173,495.89AUD | +7.42% | |
| 161,515.58AUD | -7.39% | |
| 174,410.69AUD | +154.37% | |
| 68,566.83AUD | -7.98% | |
| 74,511.75AUD | +14.60% | |
| 65,018.19AUD | +270.53% | |
| 17,547.50AUD | -13.35% | |
| 20,250.00AUD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cyclopharm Stock analysis
Frequently Asked Questions about Cyclopharm stock
PP&E per Employee of Cyclopharm is 372,133.89 AUD in 2025.
PP&E per Employee of Cyclopharm changed from 363,884.17 AUD to 372,133.89 AUD, representing a 2.27% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of PP&E per Employee Cyclopharm since 2006 – with annual values, charts, and detailed analysis.
PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.
PP&E per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Cyclopharm historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Workforce — Cyclopharm
All Key Metrics — Cyclopharm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth